Mepsevii FDA Approval History
FDA Approved: Yes (First approved November 15, 2017)
Brand name: Mepsevii
Generic name: vestronidase alfa
Dosage form: Injection
Company: Ultragenyx Pharmaceutical Inc.
Treatment for: Mucopolysaccharidosis Type VII
Mepsevii (vestronidase alfa) is a recombinant human lysosomal beta glucuronidase indicated for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).
Development timeline for Mepsevii
| Date | Article |
|---|---|
| Nov 15, 2017 | Approval FDA Approves Mepsevii (vestronidase alfa) for Mucopolysaccharidosis Type VII |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
